Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas. ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997. Physiological ALK participates in embryonic nervous system development, but its expression decreases after birth. ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase.
6-Demethoxytangeretin
From $220
A83-01 --- an ALK inhibibitor
From $79
ALK inhibitor 1
From $135
ALK inhibitor 2
From $90
ALK-IN-13
$100
ASP3026
From $90
AZD-3463
From $85
Brigatinib-analog
From $88
CEP-37440
From $195
CH5424802
From $75
CH5424802 Hydrochloride
From $75
Crizotinib
From $75
Crizotinib Hydrochloride
From $115
GSK1838705A
From $90
HG-14-10-04
From $95
KRCA-0008
From $95
LDK378
From $80
LDK378 dihydrochloride
From $80
NVP-TAE684
From $89
PF-06463922
From $90
TL 13-110
From $365
TL 13-112
From $370
TL 13-22
From $365
ZX-29
$100